Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 3,018,760 | 2,793,957 | 2,393,607 | 2,212,304 | 2,093,669 |
| Cost of Goods | 1,905,452 | 1,773,519 | 1,573,042 | 1,427,596 | 1,324,696 |
| Gross Profit | 1,113,308 | 1,020,438 | 820,565 | 784,708 | 768,973 |
| Operating Expenses | 719,664 | 771,631 | 616,233 | 880,232 | 616,953 |
| Operating Income | 394,096 | 249,326 | 204,374 | -94,928 | 152,716 |
| Interest Expense | 241,091 | 258,595 | 210,629 | 158,377 | 136,325 |
| Other Income | -13,796 | -45,744 | -34,015 | 5,178 | 14,975 |
| Pre-tax Income | 139,209 | -55,013 | -40,270 | -248,127 | 31,366 |
| Income Tax | 11,276 | 18,863 | 8,452 | 6,662 | 11,196 |
| Net Income Continuous | 127,933 | -73,876 | -48,722 | -254,789 | 20,170 |
| Minority Interests | 55,876 | 43,010 | 35,271 | -124,803 | 9,546 |
| Net Income | $72,057 | $-116,886 | $-83,993 | $-129,986 | $10,624 |
| EPS Basic Total Ops | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 |
| EPS Basic Continuous Ops | 0.41 | -0.24 | -0.28 | -1.69 | 0.14 |
| EPS Diluted Total Ops | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 |
| EPS Diluted Continuous Ops | 0.39 | -0.24 | -0.28 | -1.69 | 0.13 |
| EPS Diluted Before Non-Recurring Items | 0.75 | 0.51 | 0.55 | 0.60 | 0.71 |
| EBITDA(a) | $640,099 | $514,614 | $445,322 | $153,842 | $395,325 |